JP2023547441A - 萎縮型加齢黄斑変性、地図状萎縮および緑内障関連神経変性の処置において使用するためのｎｏ－ｐｄｅ５阻害剤 - Google Patents

萎縮型加齢黄斑変性、地図状萎縮および緑内障関連神経変性の処置において使用するためのｎｏ－ｐｄｅ５阻害剤 Download PDF

Info

Publication number
JP2023547441A
JP2023547441A JP2023526007A JP2023526007A JP2023547441A JP 2023547441 A JP2023547441 A JP 2023547441A JP 2023526007 A JP2023526007 A JP 2023526007A JP 2023526007 A JP2023526007 A JP 2023526007A JP 2023547441 A JP2023547441 A JP 2023547441A
Authority
JP
Japan
Prior art keywords
compound
pyrimidin
methyl
formula
nitrooxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547441A5 (enExample
Inventor
ナヴラティル，トーマス
インパグナッティエッロ，フランチェスコ
アルミランテ，ニコレッタ
Original Assignee
ニコックス エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニコックス エス．エー． filed Critical ニコックス エス．エー．
Publication of JP2023547441A publication Critical patent/JP2023547441A/ja
Publication of JP2023547441A5 publication Critical patent/JP2023547441A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023526007A 2020-11-02 2021-10-28 萎縮型加齢黄斑変性、地図状萎縮および緑内障関連神経変性の処置において使用するためのｎｏ－ｐｄｅ５阻害剤 Pending JP2023547441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20205111.6 2020-11-02
EP20205111 2020-11-02
PCT/EP2021/079958 WO2022090379A1 (en) 2020-11-02 2021-10-28 No-pde5 inhibitor for use in treating dry age-related macular degeneration, geographic atrophy and glaucoma-associated neurodegeneration

Publications (2)

Publication Number Publication Date
JP2023547441A true JP2023547441A (ja) 2023-11-10
JP2023547441A5 JP2023547441A5 (enExample) 2024-10-29

Family

ID=73043154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526007A Pending JP2023547441A (ja) 2020-11-02 2021-10-28 萎縮型加齢黄斑変性、地図状萎縮および緑内障関連神経変性の処置において使用するためのｎｏ－ｐｄｅ５阻害剤

Country Status (5)

Country Link
US (1) US20230414621A1 (enExample)
EP (1) EP4236952A1 (enExample)
JP (1) JP2023547441A (enExample)
CN (1) CN116456963A (enExample)
WO (1) WO2022090379A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020030489A1 (en) * 2018-08-06 2020-02-13 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
US20020168424A1 (en) 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
CA2986769A1 (en) 2015-05-27 2016-12-01 Neurotech Usa, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders
SMT202200190T1 (it) 2015-11-16 2022-07-21 Topadur Pharma Ag Derivati del 2-fenil-3,4-diidropirrolo[2,1-f] [1,2,4]triazinone come inibitori della fosfodesterasi e loro usi
US20190152967A1 (en) 2016-04-04 2019-05-23 The Schepens Eye Research Institute, Inc. Peroxisome proliferator-activated receptor gamma selective agonists for inhibition of retinal pigment epithelium degeneration or geographic atrophy
MX2019013626A (es) 2017-05-22 2020-01-13 Topadur Pharma Ag Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos.
BR112021009958A2 (pt) * 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
EP4100014B1 (en) * 2020-02-05 2024-01-03 Nicox S.A. Compositions for the treatment of glaucoma and ocular hypertension

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020030489A1 (en) * 2018-08-06 2020-02-13 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor

Also Published As

Publication number Publication date
EP4236952A1 (en) 2023-09-06
CN116456963A (zh) 2023-07-18
WO2022090379A1 (en) 2022-05-05
US20230414621A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP7774170B2 (ja) 翼状片を治療するための組成物及び方法
JP2005504101A (ja) 緑内障を治療するためのグリコゲンシンターゼキナーゼ−３（ｇｓｋ−３）インヒビター
CN101678006A (zh) 含有非麦角类的选择性d2受体激动剂作为有效成分的后眼部疾病的预防或治疗剂
JP2018522942A (ja) 視力障害を低減するための組成物及び方法
JP2021503449A (ja) 眼障害の処置のための組成物及び方法
JP2011088938A (ja) 眼血管新生疾患の処置のためのスタウロスポリン誘導体の使用
JP2003506394A (ja) 視力の保持を容易にするために視神経、脈絡膜、および網膜の血流を増大させるための方法
US10973758B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
JP5503879B2 (ja) 視神経障害を伴う眼疾患の予防又は治療剤
CN1298304A (zh) 用于预防和治疗由眼底组织细胞病变引起的疾病的药物组合物
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
JP2023547441A (ja) 萎縮型加齢黄斑変性、地図状萎縮および緑内障関連神経変性の処置において使用するためのｎｏ－ｐｄｅ５阻害剤
HK40091616A (zh) 用於治疗干性年龄相关性黄斑变性、地图状萎缩和青光眼相关性神经变性的no-pde5抑制剂
WO2019065838A1 (ja) ピリジルアミノ酢酸化合物を含有する医薬
Mokbel et al. Rho-Kinase Inhibitors as a novel medication for Glaucoma Treatment–A Review of the literature
JP2004331502A (ja) 視神経細胞保護剤
WO2006123675A1 (ja) アミジノ誘導体を有効成分として含む神経細胞の保護剤
CA2398900A1 (en) Therapeutic agents for opthalmopathy
WO2025135087A1 (ja) 慢性移植片対宿主病における眼合併症の予防治療用医薬組成物
JP4393863B2 (ja) 視神経細胞保護剤
JP2025505847A (ja) 前部虚血性視神経症の処置に使用するためのｐｄｅ５阻害剤
JP2009079041A (ja) リチウム塩を有効成分として含有する後眼部疾患の治療又は予防剤
JP2006348024A (ja) アミジノ誘導体を有効成分として含む神経細胞の保護剤
JPWO1997038691A1 (ja) 網膜神経障害治療剤
EP2632449A1 (en) Treatment of ocular and cerebral ischemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260304